Last reviewed · How we verify
BNT162b2 Bivalent (WT/OMI BA.1) (bnt162b2-bivalent-wt-omi-ba-1)
BNT162b2 Bivalent (WT/OMI BA.1) (generic name: bnt162b2-bivalent-wt-omi-ba-1) is a mRNA vaccine drug developed by Pfizer. It is currently FDA-approved for Prevention of COVID-19 in individuals 12 years of age and older, Prevention of COVID-19 in individuals 5 years of age and older, Prevention of COVID-19 in individuals 6 months through 4 years of age.
BNT162b2 Bivalent (WT/OMI BA.1) is a marketed COVID-19 vaccine developed by Pfizer Inc. It prevents COVID-19 in individuals 12 years and older, 5 years and older, and 6 months through 4 years of age. The vaccine has generated $21.2B in revenue. Its mechanism is not specified. The vaccine has one clinical trial and no publications. It is a marketed vaccine, indicating its clinical differentiation and commercial significance. There are no pipeline developments mentioned.
At a glance
| Generic name | bnt162b2-bivalent-wt-omi-ba-1 |
|---|---|
| Sponsor | Pfizer |
| Drug class | mRNA vaccine |
| Target | SARS-CoV-2 spike protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of COVID-19 in individuals 12 years of age and older
- Prevention of COVID-19 in individuals 5 years of age and older
- Prevention of COVID-19 in individuals 6 months through 4 years of age
Common side effects
- Injection site pain (PAIN)
- Fatigue (FATIGUE)
- Headache (HEADACHE)
- Myalgia (MUSCLE PAIN)
- Chills (CHILLS)
- Arthralgia (JOINT PAIN)
- Diarrhoea (DIARRHEA)
- Injection site swelling (SWELLING)
- Injection site erythema (REDNESS)
- COVID-19
- Pyrexia (FEVER)
- Vomiting (VOMITING)
Drug interactions
- Warfarin
- Aspirin
- Pain medications
- Anticoagulants
- Antiplatelets
- Corticosteroids
- Live vaccines
- Immunosuppressants
Key clinical trials
- A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b2 Bivalent (WT/OMI BA.1) CI brief — competitive landscape report
- BNT162b2 Bivalent (WT/OMI BA.1) updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about BNT162b2 Bivalent (WT/OMI BA.1)
What is BNT162b2 Bivalent (WT/OMI BA.1)?
What is BNT162b2 Bivalent (WT/OMI BA.1) used for?
Who makes BNT162b2 Bivalent (WT/OMI BA.1)?
What is the generic name of BNT162b2 Bivalent (WT/OMI BA.1)?
What drug class is BNT162b2 Bivalent (WT/OMI BA.1) in?
What development phase is BNT162b2 Bivalent (WT/OMI BA.1) in?
What are the side effects of BNT162b2 Bivalent (WT/OMI BA.1)?
What does BNT162b2 Bivalent (WT/OMI BA.1) target?
Related
- Drug class: All mRNA vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of COVID-19 in individuals 12 years of age and older
- Indication: Drugs for Prevention of COVID-19 in individuals 5 years of age and older
- Indication: Drugs for Prevention of COVID-19 in individuals 6 months through 4 years of age
- Compare: BNT162b2 Bivalent (WT/OMI BA.1) vs similar drugs
- Pricing: BNT162b2 Bivalent (WT/OMI BA.1) cost, discount & access